The WRADIANCE© Instrument and Protocol is an assessment approach designed for assessing autism in women, and has been in development for three years. Phase I has been completed, with Phase II entering the final data analysis stage in preparation for Phase III, which is Clinical Trial. The WRADIANCE© has involved direct input from nearly 1,000 autistic women across the world and we are grateful for their participation, interest, and contributions made as this new instrument takes shape.
Interested neurodivergent (or neurodivergent-affirming) clinicians — whether counselors, therapists, psychologists, social workers — who are interested in potentially participating in the Phase III Clinical Trial, anticipated to begin in early-to-mid 2026, are welcome to add their name and contact information via the link below.
Clinician Expression of Interest Form: WRADIANCE© Phase III Clinical Trial